Vallon Pharmaceuticals

[On Demand]
Search General Info
Search Education
Search Partnering Companies
Vallon Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel abuse-deterrent medications for CNS disorders. The Company’s lead investigational product candidate, ADAIR (Abuse-Deterrent Amphetamine Immediate-Release), is a proprietary abuse-deterrent formulation of immediate release (IR) dextroamphetamine in development for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. ADAIR is designed to deter attempts to crush and snort and provides barriers to injection.
Ticker:
VLON
Exchange:
NASDAQ
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Pennsylvania
Company HQ Country:
United States
Year Founded:
2018
Main Therapeutic Focus:
Lead Product in Development:
ADAIR (Abuse Deterrent Amphetamine Immediate Release)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
photo
Chief Executive Officer
Vallon Pharma